CHEMOCENTRYX sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive
The independent financial analyst theScreener just awarded an improved star rating to CHEMOCENTRYX (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 15, 2022, the closing price was USD 31.59 and its target price was estimated at USD 8.61.ChemoCentryx is a biopharmaceutical company developing medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of the company's drug candidates is designed to selectively block a specific chemoattractant receptor. The company's drug candidates are small molecules, which are orally administered. The company's product development portfolio features drug candidates in therapeutic areas of immunology, oncology and immuno-oncology. The company's primary drug candidate is avacopan, an orally-administered molecule that employs a targeted mode of action in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis and other complement-driven autoimmune and inflammatory diseases.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.